Science Current Events | Science News | Brightsurf.com
 

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

April 03, 2012
CHICAGO - A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

American Association for Cancer Research


Related Bevacizumab Current Events and Bevacizumab News Articles


BNI study reveal unexpected findings
"The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizuman had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival."

Promising cervical cancer study
Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine.

Bevacizumab offers no benefit for newly diagnosed glioblastoma, MD Anderson-led study finds
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.

Marker may predict response to ipilimumab in advanced melanoma
Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.

Phase II Trial of Bevacizumab (Avastin) in Locally Advanced Cervical Cancer "Promising"
An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer.

Personalized vaccine for most lethal type of brain tumor shows promise
Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone.

PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant
Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene.

Study identifies highly effective treatment option for patients with HER2-positive breast cancer
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes.

Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
A University of Colorado Cancer Center study published in the journal PLoS One shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor.

New eye treatment effective in laboratory tests
A promising technique for treating human eye disease has proven effective in preclinical studies and may lead to new treatments to prevent blindness, according to experiments conducted at The Scripps Research Institute (TSRI) in La Jolla, California.
More Bevacizumab Current Events and Bevacizumab News Articles

Bevacizumab: Webster's Timeline History, 2001 - 2007

Bevacizumab: Webster's Timeline History, 2001 - 2007
by Icon Group International (Author)


Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Bevacizumab," including when used in literature (e.g. all authors that might have Bevacizumab in their name). As such, this book represents the largest compilation of timeline events associated with Bevacizumab when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...

  Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article): An article from: Family Practice News
by Jeff Evans (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on September 1, 2003. The length of the article is 1131 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab stalls metastatic kidney Ca growth: no increase in overall survival rate.(Rx)(Brief Article)
Author: Jeff Evans
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2003
Publisher: International Medical News Group
Volume: 33 Issue: 17 Page: 42(1)

Article Type: Brief Article

Distributed by Thomson...

  Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds): An article from: Internal Medicine News
by Jeff Evans (Author)


This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 318 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab can slow metastatic kidney cancer; no rise in overall survival.(Clinical Rounds)
Author: Jeff Evans
Publication: Internal Medicine News (Magazine/Journal)
Date: October 1, 2003
Publisher: International Medical News Group
Volume: 36 Issue: 19 Page: 26(1)

Distributed by Thomson...

  Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology): An article from: Internal Medicine News
by International Medical News Group (Publisher)


This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2005. The length of the article is 530 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improves survival in patients with colorectal cancer.(Gastroenterology)
Publication: Internal Medicine News (Magazine/Journal)
Date: April 1, 2005
Publisher: International Medical News Group
Volume: 38 Issue: 7 Page: 69(1)

Distributed by Thomson...

  Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by International Medical News Group on June 15, 2005. The length of the article is 1884 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab aids survival in breast, lung, colorectal cancer: antiangiogenesis agent appears effective.(News)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: June 15, 2005
Publisher: International Medical News Group
Volume: 35 Issue: 12 Page: 1(2)

Distributed by Thomson...

  Bevacizumab improved survival in leading cancers.(Clinical Rounds): An article from: Skin & Allergy News
by Jane Salodof MacNeil (Author)


This digital document is an article from Skin & Allergy News, published by International Medical News Group on July 1, 2005. The length of the article is 1396 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab improved survival in leading cancers.(Clinical Rounds)
Author: Jane Salodof MacNeil
Publication: Skin & Allergy News (Magazine/Journal)
Date: July 1, 2005
Publisher: International Medical News Group
Volume: 36 Issue: 7 Page: 60(1)

Distributed by Thomson...

  Bevacizumab aids survival in cancer.(News): An article from: Internal Medicine News
by Jane Salodof MacNeil (Author)


This digital document is an article from Internal Medicine News, published by Thomson Gale on June 15, 2005. The length of the article is 1903 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab aids survival in cancer.(News)
Author: Jane Salodof MacNeil
Publication: Internal Medicine News (Magazine/Journal)
Date: June 15, 2005
Publisher: Thomson Gale
Volume: 38 Issue: 12 Page: 1(3)

Distributed by Thomson...

  Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine): An article from: Family Practice News
by Jane Salodof MacNeil (Author)


This digital document is an article from Family Practice News, published by Thomson Gale on September 1, 2006. The length of the article is 713 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab-erlotinib combo boosts lung cancer survival.(Pulmonary Medicine)(cancer medicine)
Author: Jane Salodof MacNeil
Publication: Family Practice News (Magazine/Journal)
Date: September 1, 2006
Publisher: Thomson Gale
Volume: 36 Issue: 17 Page: 43(1)

Distributed by Thomson...

  Bevacizumab: An entry from Thomson Gale's Gale Encyclopedia of Cancer, 2nd ed.
by Tish, A. M. Davidson (Author)


Students, researchers, and patients can find reliable, up-to-date and clearly written information in “The Gale Encyclopedia of Cancer,” a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures.

  Bevacizumab disappoints in pancreatic cancer.(Gastroenterology): An article from: Internal Medicine News
by Gale Reference Team (Author)


This digital document is an article from Internal Medicine News, published by Thomson Gale on April 1, 2007. The length of the article is 456 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Bevacizumab disappoints in pancreatic cancer.(Gastroenterology)
Author: Gale Reference Team
Publication: Internal Medicine News (Magazine/Journal)
Date: April 1, 2007
Publisher: Thomson Gale
Volume: 40 Issue: 7 Page: 44(1)

Distributed by Thomson...

© 2014 BrightSurf.com